Mechanism of Action and Clinical Implications of Dexmethylphenidate

Primary Neurotransmitter Effects and Clinical Implications

Dexmethylphenidate increases the efficiency of prefrontal cortex activity and optimizes executive and attentional function in patients with ADHD, by enhancing the impact of dopamine and norepinephrine 1
Methylphenidate (the parent compound) demonstrates agonist activity at the serotonin type 1A receptor, contributing to its overall therapeutic effects 1
The drug causes redistribution of the vesicular monoamine transporter 2, further modulating neurotransmitter availability 1

The immediate-release component provides rapid symptom control within 30 minutes, while the delayed-release component maintains therapeutic levels throughout the day 2
Stimulant medication effects on ADHD are concentrated within the early part of the absorption phase, with monoamine neurotransmitters pulsing into the synaptic cleft during rapid concentration changes 2

The increased dopamine and norepinephrine activity significantly enhances executive function, working memory, and inhibitory control in the prefrontal cortex 1
This translates to decreased interrupting, fidgeting, and finger tapping; increased on-task behavior; improved parent-child interactions; and enhanced compliance in real-world settings 3
Dexmethylphenidate decreases response variability and impulsive responding on cognitive tasks 2
The drug increases accuracy of performance and improves short-term memory, reaction time, math computation, problem-solving, and sustained attention 3

There is little evidence of tolerance development to stimulant effects on ADHD symptoms with chronic use 2
However, short-term tolerance can develop by the second dose given in the same day, which is why extended-release formulations maintain efficacy by providing gradually increasing blood levels throughout the day 2